CASE
A 24-year-old Middle Eastern man diagnosed with hemophilia at the age of 4 or 5 years presented to the hematology clinic for follow-up after a recent hospitalization for excessive bleeding from an accidental knife cut. The patient reported a history of prolonged bleeding after teeth extractions, an upper gastrointestinal bleed 3 years previously, and excessive bruising since childhood. He denied hemarthroses but reported chronic pain in his ankles and joints. The patient reported having been treated for episodes of excessive bleeding with fresh frozen plasma (FFP) 3 and factor VIII during past hospitalizations. Because of poor continuity of care, his disease had not been monitored or treated on an ongoing outpatient basis. The patient's family history is noteworthy for consanguineous parents (first cousins) and a sister who also experienced excessive bleeding, although her diagnosis was uncertain. Initial laboratory test results included a normal complete blood count, including platelets, a prolonged activated partial thromboplastin time (aPTT), and a prolonged prothrombin time (PT) ( Table 1) . Fibrinogen activity was normal. A 1:1 mixture of the patient's plasma with pooled normal plasma demonstrated full correction of the PT and aPTT, a result consistent with factor deficiency.
DISCUSSION ADDITIONAL PATIENT DATA AND DIFFERENTIAL DIAGNOSIS
Patients with isolated hemophilia A, B, or C (due to deficiencies in factors VIII, IX, and XI, respectively) or factor VIII deficiency due to von Willebrand disease typically have a prolonged aPTT but a normal PT. In the absence of anticoagulation therapy or suspected vitamin K deficiency, a prolonged PT in this patient's initial workup should raise clinical suspicion for a bleeding disorder of a different etiology. Given the patient's clinically notable bleeding symptoms since childhood, a genetic disorder should be considered. The differential diagnosis includes dysfibrinogenemia, prothrombin deficiency, factor V deficiency, combined deficiency of factors V and VIII (F5F8D), factor X deficiency, and hereditary combined deficiency of the vitamin K-dependent clotting factors. All of these conditions feature prolongation of both the PT and the aPTT (1 ) . Given the results of the mixing studies, we subsequently evaluated factor activities ( Table 1) .
The results of additional coagulation studies strongly suggested a diagnosis of F5F8D, because activities of factors V and VIII activities were markedly decreased. Also, factor VII activity appeared to be slightly increased, but this finding was considered unlikely to be of clinical consequence. F5F8D is a genetic condition that is often misdiagnosed as a single-factor deficiency condition such as hemophilia A, particularly in institutions with limited diagnostic resources in hematology (2 ) . The inheritance pattern and pathogenesis of these 2 genetic disorders are distinct and are important for both therapeutic and genetic-counseling purposes. This scenario underscores the importance of further laboratory investigation when initial testing appears to be inconsistent with the patient's supposed diagnosis.
In the coagulation cascade, factors V and VIII are glycoprotein cofactors for the proteolytic activation of prothrombin (factor II) by factor X and of factor X by factor IX, respectively, and thus are essential for clot formation. F5F8D is a rare autosomal recessive disorder in which plasma concentrations of factors V and VIII are both decreased, thus leading to the symptoms of excessive bleeding. The incidence of this condition is approximately 1 in 1 000 000 in the general population but reportedly is more prevalent among Middle Eastern Jewish and non-Jewish Iranian populations, for which the incidence is estimated to be 1 in 100 000. The higher degree of consanguinity in these populations is thought to partially explain the higher prevalence of this autosomal recessive disorder (3 ).
F5F8D is genetically distinct from isolated inherited deficiencies of factor VIII (hemophilia A) and factor V (parahemophilia). Although having hemophilia A and a concurrent factor V deficiency is possible, such a combination is much less probable given the distinct inheritance patterns of the 2 conditions. Family history is also important to consider. Because this patient also has a sister with a similar bleeding disorder, it is unlikely that hemophilia A, which typically affects only males because of its X-linked inheritance, is the etiology (3 ). Clinically, patients with hemophilia A present in childhood similarly to those with F5F8D-easy bruising, nosebleeds, and severe bleeding after surgical procedures, dental extractions, and trauma. Menorrhagia and postpartum hemorrhage are common in affected women (1 ) . Autosomal recessive factor V deficiency, which also presents in childhood and is associated with parental consanguinity, presents with easy bruising, nosebleeds, and mucous membrane bleeding, particularly within the oral cavity (1 ). Hemarthroses, muscle hematomas, and spontaneous bleeding are less likely to be observed in patients with factor V deficiency and in those with F5F8D compared to patients with severe hemophilia A (1 ). The bleeding severity in patients with F5F8D is ultimately similar to that experienced by patients with similar deficiency levels of either of these factors alone (4 ) . The results of the coagulation studies, the clinical presentation, and the family history for the patient described in this case indicate F5F8D as the most likely diagnosis. Molecular genetic testing would be needed to absolutely confirm this diagnosis. For diagnostic and treatment purposes, however, assays of factors V and VIII assays are sufficient (2 ) .
Currently, mutations in either of 2 genes, LMAN1
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(lectin, mannose-binding, 1) and MCFD2 (multiple coagulation factor deficiency 2), are believed to account for all cases of F5F8D. LMAN1 and MCFD2 encode proteins that form a calcium-dependent complex essential for transporting factors V and VIII from the endoplasmic reticulum to the Golgi apparatus in coat protein II-coated vesicles (Fig. 1) . Interestingly, factors V and VIII are the only cargo proteins known to be affected in patients with F5F8D. If the transport of other cargo proteins is affected, the deficiency likely is not large enough to produce a clinical phenotype (2, 5 ) .
CLINICAL MANAGEMENT
As in most bleeding conditions, the guidelines for the clinical management of F5F8D are dictated by the severity of the disease. In F5F8D, both the nature of the bleeding and the activities of factors V and VIII activities are used to guide therapy. Regular prophylaxis is not usually necessary unless the patient has recurrent severe hematomas and hemarthroses (2 ). For minor bleeding episodes, factor VIII activity should be increased to 30%-50% of normal; for more-severe bleeding episodes, factor VIII activity should be increased to 50%-70%. For bleeding episodes in general, factor V activity should be increased to 25% (1 ). Sources of both factors are required for adequate hemostasis. Because no factor V concentrates are available at this time, FFP is the only product available for factor V replacement. Although FFP theoretically may be used to replace both factors, it is important to remember 
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that factors V and VIII differ in the recommended concentrations needed for hemostasis and have different plasma half-lives (36 h for factor V and 10 -14 h for factor VIII) (5 ). Thus, replacing factor VIII with FFP alone would necessitate substantially more exposure to blood products. Factor VIII concentrates can be used to supplement FFP to achieve an adequate factor VIII concentration. Numerous types of factor VIII concentrates are available and are in widespread use for patients with hemophilia A. Desmopressin has been reported to be useful for minor bleeding episodes in F5F8D to further increase the factor VIII concentration (6 ) . Patients undergoing surgical procedures require appropriate prophylactic therapy: administration of factor VIII concentrates every 12 h to maintain the factor VIII activity at Ͼ50% and FFP every 12 h to achieve the factor V activity at Ͼ25%, until wound healing occurs (1 ).
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Fig. 1. Illustration of factor V (FV) and factor VIII (FVIII) transport from the endoplasmic reticulum to the Golgi apparatus, facilitated by the calcium-dependent LMAN1-MCFD2 complex.
FV and FVIII leave the endoplasmic reticulum in coat protein II (COPII)-coated vesicles and are further modified in the Golgi apparatus before exiting the cell.
POINTS TO REMEMBER
• Clinical and family histories pertaining to bleeding abnormalities are extremely important in evaluating hereditary coagulation disorders.
• Further laboratory investigation is necessary when supposed diagnoses, family history, and the results of initial laboratory studies are inconsistent.
• Although rare, F5F8D should be suspected in patients who claim to have hemophilia and have a prolonged PT and a prolonged aPTT, particularly if they are of Middle Eastern heritage and/or have a family history of consanguinity. It is therefore necessary to include factors V and VIII in testing for unexplained factor deficiencies in the setting of prolongation of both PT and aPTT.
• In patients with F5F8D and an acute bleeding episode, both factor V and factor VIII need to be replaced. FFP must be given to replace factor V because no other source of factor V is currently available.
Commentary
Elizabeth M. Van Cott * This case highlights the importance of confirming the diagnosis when first seeing a patient with reportedly known hemophilia. If original laboratory reports are not available, repeat testing is suggested. First, it is important to be certain about which factor (VIII, IX, or XI) is low. There was a case at another facility where a new hemophilia patient received factor VIII concentrate for a bleeding event, but actually had hemophilia B (factor IX deficiency). Second, laboratories must test factors at multiple dilutions to rule out an inhibitor (e.g., lupus anticoagulant, heparin, or direct thrombin inhibitor). For example, a patient with a diagnosis of hemophilia C (factor XI deficiency), who had moved from another state, was seen at my institution. Our testing revealed, however, that only the 1:10 dilution (1 volume of sample in 9 volumes of diluent) revealed a low factor XI activity, and the factor XI activity increased with dilution, such that a 1:40 dilution (1 volume sample in 39 volumes diluent) had normal factor XI activity. We found that the patient had a lupus anticoagulant interfering in the factor XI assay, which cause a false reduction in factor XI activity. For the 20 years before these tests, he had received unnecessary fresh frozen plasma preoperatively, and the lupus anticoagulant's thrombotic risk had not been realized. If factor VIII is low, other entities need to be considered before diagnosing hemophilia A. Factor VIII is labile and can be falsely low if the sample has clotted, has been kept as whole blood on ice, or has undergone repeated freeze/thaw cycles. Disseminated intravascular coagulation can consume factor VIII. von Willebrand disease, when severe enough, causes low factor VIII. Importantly, normal von Willebrand factor results do not exclude type 2N von Willebrand disease, which is characterized by a factor VIII activity 5%-40% of normal, owing to a von Willebrand factor mutation that impairs its ability to bind and protect factor VIII. Type 2N von Willebrand disease can be distinguished from hemophilia A by the inheritance pattern (autosomal vs X-linked, respectively) or, if necessary, by a factor VIII-binding assay or genetic tests at a reference laboratory. As shown in this case, it is important that the prothrombin and activated partial thromboplastin times also be assessed to screen for other causes of low factor VIII activity, such as combined deficiencies of factors V and VIII, clotted sample, or disseminated intravascular coagulation.
The most efficient approach is to start with measuring the prothrombin and activated partial thromboplastin times in a laboratory that reflexively performs mixing studies, factor assays, and/or lupus anticoagulant testing, as indicated.
